On May 12, 2026, a peer-reviewed paper published in The Lancet — one of the world's oldest and most respected medical journals — formally announced that Polycystic Ovary Syndrome (PCOS) would be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The paper, led by Professor Helena Teede at Monash University in Melbourne, represents the conclusion of a 14-year multistep process involving 56 academic, clinical, and patient organisations across six continents.
What Exactly Changed?
The condition itself did not change. The diagnostic criteria did not change. If you have a PCOS diagnosis, that diagnosis remains completely valid. What changed is the official name — and the reasoning behind that change has been building in the medical community for over a decade.
Why Was the Old Name a Problem?
The case for renaming PCOS did not appear suddenly in 2026. It had been building in the published medical literature for years — with a pivotal moment coming in 2012, when the United States National Institutes of Health convened a formal Evidence-Based Methodology Workshop specifically on PCOS. The NIH panel's final report described the name as "a distraction and an impediment to progress" and recommended renaming as a priority.
The "cysts" are not cysts
The "polycystic" in PCOS refers to the appearance of multiple small follicles on ovarian ultrasound. These are arrested antral follicles — not true pathological cysts. Calling them cysts has caused widespread patient anxiety and diagnostic confusion for decades, with many women told they do not have PCOS because no cysts were found on their scan.
You do not need polycystic ovaries to be diagnosed
Under the Rotterdam Criteria — the internationally accepted diagnostic standard since 2003 — a patient only needs two of three features to receive a PCOS diagnosis: irregular ovulation, signs of hyperandrogenism, or polycystic ovary morphology on ultrasound. This means someone can have the syndrome without ever showing polycystic ovaries. A condition named after a feature that is not required for its diagnosis is, by definition, misnamed.
The name hides the metabolic reality
PCOS/PMOS is now understood to be a systemic endocrine and metabolic condition. It involves insulin resistance (present in the majority of cases regardless of weight), elevated androgen levels, dysregulation of the hypothalamic-pituitary-ovarian axis, and significantly increased risks of Type 2 diabetes, cardiovascular disease, and metabolic syndrome. An ovary-centric name has historically directed the condition toward gynaecology — when it equally belongs to endocrinology, metabolism, and general medicine.
The name delayed diagnosis and limited research funding
The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS — developed under the auspices of ESHRE and endorsed by more than 40 organisations — explicitly acknowledged that the name had contributed to misperceptions of the condition as primarily gynaecological. This framing influenced research funding decisions, clinical training, and how specialists engaged with the condition. The name shaped what questions got asked — and what questions did not.
Patients supported it
A longitudinal international survey published in eClinicalMedicine (The Lancet family) in 2025 — involving 7,708 patients and health professionals across six continents, measured in both 2015 and 2023 — found that 85.6% of patients and 76.1% of health professionals supported changing the name. Patients cited reduced stigma, clearer communication, and better scientific accuracy as their primary reasons.
The 14-Year Consensus Process
What makes the PMOS renaming significant is not just what changed — it is how carefully it was done. This was not a unilateral decision by a single organisation or a change driven by a single paper. It was a structured, multistep, international process specifically designed to build genuine consensus.
The final vote was 87 in favour of PMOS out of 90 participants. The two other candidate names that reached the final round were Endocrine Metabolic Ovulatory Syndrome and Ovulatory Metabolic Endocrine Syndrome. PMOS was selected for retaining the ovarian component — which remains clinically important — while adding the polyendocrine and metabolic dimensions that the old name entirely omitted.
Key organisations whose representatives participated in and endorsed the process include the Endocrine Society, the Androgen Excess and PCOS Society (whose president Professor Terhi Piltonen and executive director Professor Anuja Dokras were named co-authors on the Lancet paper), Verity (the leading PCOS patient charity in the UK, whose chair Rachel Morman was also a co-author), the Black Women's Health Imperative, and dozens of other clinical and research bodies.
What This Means for Your Diagnosis and Care
If you have been diagnosed with PCOS, that diagnosis is completely valid and does not need to be re-done. The renaming does not alter the Rotterdam Criteria or any treatment protocols. PMOS and PCOS describe the same condition — one with a name that more accurately reflects what is actually happening in your body.
In practical terms, the transition will be gradual. International disease classification systems — including the ICD codes used in clinical records, insurance billing, and public health data — have not yet been updated as of this writing. Clinical adoption of the new name will take time as medical education programmes, institutional systems, and prescribing guidelines catch up to the published consensus.
What this means for you today:
You may see both names used
Your medical records, lab forms, and doctor's language will likely continue to say "PCOS" for the foreseeable future. This does not mean your care is outdated — it simply reflects the pace at which clinical systems update. PCOS and PMOS refer to the same condition.
The name change strengthens the case for metabolic care
PMOS explicitly names the metabolic dimension of the condition. This matters clinically: it makes it harder to dismiss insulin resistance testing, cardiovascular monitoring, and metabolic management as "optional" elements of PCOS care. The name now reflects the full scope of what requires monitoring and treatment.
Research funding should follow
One documented consequence of the ovary-centric name was that PCOS was historically underfunded relative to its prevalence — affecting 1 in 10 women of reproductive age — because it was perceived as primarily a reproductive or gynaecological condition rather than a systemic one. A name that signals metabolic and endocrine complexity may support more appropriate research investment going forward.
You may be diagnosed more accurately
A clearer name may reduce the single most common cause of missed diagnosis: patients — and clinicians — believing that an absent polycystic ovary finding on ultrasound rules out the syndrome. Under both the old diagnostic criteria and the new name, polycystic ovary morphology is just one of three possible diagnostic features — and only two are required.
What Dissenting Voices Said
The consensus was strong — 87 out of 90 votes — but not unanimous, and the concerns raised by those who dissented deserve honest representation.
PCOS Challenge, the leading patient advocacy organisation in the United States, cast one of the two dissenting votes. Executive Director Sasha Ottey raised two primary concerns: first, that emerging science is exploring whether a male-equivalent of the condition may exist, and the new name may not accommodate that possibility; second, that changing a widely recognised acronym requires substantial public re-education, and that effort carries real costs in awareness and understanding for current patients. Angela Grassi, CEO of the PCOS Nutrition Center, also publicly dissented on similar grounds.
These are legitimate concerns — particularly around the public re-education challenge. PCOS has taken decades to enter public consciousness, and any renaming risks temporarily reducing recognition of the condition in public health communications, media, and search engines during the transition period.
We believe the renaming is scientifically correct and ultimately beneficial for patients. We also believe the transition concerns are real. We will continue to use both terms — PCOS and PMOS — to ensure people searching for either name can find accurate information. The goal is better care for everyone with this condition, regardless of what it is called.
Whether You Call It PCOS or PMOS —
Your Type Still Determines Your Protocol
The name changed. The four phenotypes did not. The most important step is still understanding which type you have — it shapes your labs, your supplements, and what to say at your next appointment.
Find My Type — Free → No app store · No account · Nothing leaves your phone